MedTrace Logo

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

NCT03934814 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2024-07-01

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

Conditions

Interventions

DRUG

TJ011133

TJ011133 will be administered weekly.

DRUG

Pembrolizumab

Pembrolizumab will be administered every 3 weeks.

DRUG

Rituximab

Rituximab will be administered weekly for 5 doses, then followed by monthly doses.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-16
Primary Completion
2023-01-10
Completion
2023-01-10
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03934814 on ClinicalTrials.gov